At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 68 target
Drug / intervention
FTL008.16drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Dose Expansion Study of FTL008.16, a Recombinant Anti-CD137 and Anti-5T4 Bispecific Antibody, in Patients With Advanced or Metastatic Solid Tumors
In Brief
A Phase 1 clinical trial evaluating FTL008.16 for Solid Tumors. Currently recruiting, targeting 68 participants across 1 site.
Detailed Summary
This is an open, multi-center, multi-cohort phase I clinical study designed to evaluate safety, tolerability, pharmacokinetics and initial efficacy of FTL008.16 in patients with advanced and metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
202520262027
First PostedMay 2024
Enrollment StartMay 2025
TodayJul 2026
Primary CompletionNov 2026
Study CompletionNov 2027
First PostedMay 10, 2024
Enrollment StartMay 27, 2025
Primary CompletionNov 1, 2026
Study CompletionNov 1, 2027
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 2.1 years agoPrimary completion in 4 months
Interventions
FTL008.16drug
IV infusion every 2 weeks